ImmunityBio (IBRX) stock jumps after the FDA meeting on the company's plans to seek label expansion for bladder cancer therapy Anktiva. Read more here.

Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...

Gen Alpha are growing up very differently to their millennial and Gen Z parents. It’s going to change how they interact with ...

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be ...

Pirate group accused of ‘brazen theft of millions of files containing nearly all of the world’s commercial sound ...

New narrative-guided media intelligence transforms scattered digital memories into a searchable, story-aware personal ...

Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion 1 ), in line with upgraded guidance of US$800-$820 million 2 (previously US$770-800 million). Q4 2025 ...

Musician Slick Rick turns 61 and actor Adjoa Andoh turns 63, among the famous birthdays for Jan. 14.

Antsy lobbyists and lawyers, a buzzy press corps and the onslaught of news stories about the fate of President Trump‘s tariffs could lead one to believe it’s the Supreme Court’s opinion season climax ...

Foundation models show promise in medicine, but clinical use requires outputs that clinicians can act on under pre-specified error budgets, such as a cap on false ...